000130449 001__ 130449
000130449 005__ 20240125162930.0
000130449 0247_ $$2doi$$a10.1002/pros.23964
000130449 0248_ $$2sideral$$a117176
000130449 037__ $$aART-2020-117176
000130449 041__ $$aeng
000130449 100__ $$aRubio-Briones, J.
000130449 245__ $$aValidation of a 2-gene mRNA urine test for the detection of =GG2 prostate cancer in an opportunistic screening population
000130449 260__ $$c2020
000130449 5203_ $$aBackground: A 2-gene urine-based molecular test that targets messenger RNAs known to be overexpressed in aggressive prostate cancer (PCa) has been described as a helpful method for detecting clinically significant prostate cancer (grade group [GG] =2). We performed an external validation of this test in men undergoing initial prostate biopsy (Bx) within a Spanish opportunistic screening scenario. Methods: We analyzed archived samples from 492 men who underwent prostate Bx in an opportunistic screening scenario, with prostate-specific antigen (PSA) 3 to 10 ng/mL and/or suspicious digital rectal exploration (DRE) and without previous multi-parametric magnetic resonance imaging (mpMRI). Urinary biomarker measurements were combined with clinical risk factors to determine a risk score, and accuracy for GG = 2 PCa detection was compared with PCA3, European randomized screening in prostate cancer (ERSPC), and prostate biopsy collaborative group (PBCG) risk calculators in a validation workup that included calibration, discrimination, and clinical utility analysis. Results: In our cohort, the detection rates for GG1 and GG = 2 PCa were 20.3% and 14.0%, respectively. The median PSA level was 3.9 ng/mL and 13.4% of subjects had suspicious DRE findings. The median risk score for men with GG = 2 PCa was 21 (interquartile range: 14-28), significantly higher than benign+GG1 PCa (10, 6-18), P <.001, achieving the highest area under the curve among the models tested, 0.749 (95% confidence interval: 0.690-0.807). The urine test was well-calibrated, while ERSPC showed a slight underestimation and PBCG a slight overestimation of risk. Assuming a GG2 non-detection rate of 11% without using mpMRI, use of the urinary biomarker-based clinical model could have helped avoid 37.2% of excess biopsies while delaying the diagnosis of eight patients (1.6% of the entire cohort) with GG = 2 PCa. Conclusions: In this first evaluation in an opportunistic screening population, the urinary biomarker-based test improved the detection of clinically significant PCa. Facing men with elevated PSA and/or suspicious DRE, it could be a useful tool to help avoid excess initial Bx and to identify patients most likely to benefit from Bx.
000130449 540__ $$9info:eu-repo/semantics/openAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000130449 590__ $$a4.104$$b2020
000130449 591__ $$aUROLOGY & NEPHROLOGY$$b23 / 89 = 0.258$$c2020$$dQ2$$eT1
000130449 591__ $$aENDOCRINOLOGY & METABOLISM$$b69 / 144 = 0.479$$c2020$$dQ2$$eT2
000130449 592__ $$a1.294$$b2020
000130449 593__ $$aUrology$$c2020$$dQ1
000130449 593__ $$aOncology$$c2020$$dQ1
000130449 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000130449 700__ $$0(orcid)0000-0003-0178-4567$$aBorque-Fernando, A.$$uUniversidad de Zaragoza
000130449 700__ $$0(orcid)0000-0002-3007-302X$$aEsteban, L.M.
000130449 700__ $$aMascarós, J.M.
000130449 700__ $$aRamírez-Backhaus, M.
000130449 700__ $$aCasanova, J.
000130449 700__ $$aCollado, A.
000130449 700__ $$aMir, C.
000130449 700__ $$aGómez-Ferrer, A.
000130449 700__ $$aWong, A.
000130449 700__ $$aAragón, F.
000130449 700__ $$aCalatrava, A.
000130449 700__ $$aLópez-Guerrero, J.A.
000130449 700__ $$aGroskopf, J.
000130449 700__ $$aSchalken, J.
000130449 700__ $$aVan Criekinge, W.
000130449 700__ $$aDomínguez-Escrig, J.
000130449 7102_ $$11013$$2817$$aUniversidad de Zaragoza$$bDpto. Cirugía$$cÁrea Urología
000130449 773__ $$g80, 6 (2020), 500-507$$pProstate$$tPROSTATE$$x0270-4137
000130449 8564_ $$s1307876$$uhttps://zaguan.unizar.es/record/130449/files/texto_completo.pdf$$yVersión publicada
000130449 8564_ $$s2070671$$uhttps://zaguan.unizar.es/record/130449/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000130449 909CO $$ooai:zaguan.unizar.es:130449$$particulos$$pdriver
000130449 951__ $$a2024-01-25-15:11:36
000130449 980__ $$aARTICLE